UCB Group looks to have done a very smart bit of business by agreeing to buy Ra Pharmaceuticals Inc. for $2.1bn and get access to the potential blockbuster zilucoplan for the neuromuscular condition myasthenia gravis (MG) and other rare diseases.
The Belgian drugmaker is paying $48 a share in cash for Cambridge, MA-based Ra, which represents a 111% premium to...








